NIXT yields 1.53% · PFE yields 6.20%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, NIXT + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NIXT + PFE for your $10,000?
NIXT tracks an index of recently deleted US small- and mid-cap stocks screened for quality. The portfolio aims to benefit from a potential long-term reversal in the performance of these deleted stocks. The index is constructed from a pool of the top 1000 and top 500 US companies in the RAFI Global Equity Investable Universe (GEIU), which are maintained in two benchmark indices, the Cap-Weight 500 and Cap-Weight 1000. Using a five-year look-back period, the smallest stocks or those that have fallen out of the benchmark indices are identified, scored, and ranked for quality using the following metrics: debt coverage ratio, equity issuance, debt issuance, change in leverage, total payout, and net payout. The top 80% are added to the index and are equally weighted. Companies in the index have a 5-year holding period and are removed if their market cap has risen enough to re-qualify for the benchmark indexes. The index is reconstituted annually in April and rebalanced in May.
Full NIXT Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.